Updated:
Lake Bleu Capital
David Yang's Lake Bleu Capital runs a concentrated, crossover healthcare portfolio between Hong Kong and Greater China.
Lake Bleu Capital
David Yang established Lake Bleu Capital in 2016 in Hong Kong after analytical roles at two of the world's largest healthcare-dedicated investment firms, Orbimed and Hillhouse Capital. The firm emerged as a specialized healthcare investment manager for Asian markets, leveraging Yang's background in evaluating complex biomedical and healthcare services businesses. Lake Bleu operates a crossover strategy, investing in both public equities and private late-stage companies within the healthcare sector. The firm seeks opportunities where scientific complexity or regulatory hurdles obscure intrinsic value. Confirmed positions via public filings include participation in the pre-IPO rounds of Zai Lab and CStone Pharmaceuticals, two prominent China-based biopharmaceutical companies, and a known public equity stake in Wuxi Biologics. Its geographic focus spans Greater China with select exposures in the United States, particularly in biotechnology firms with Asia commercialization strategies. The firm typically writes concentrated checks and maintains long holding periods rather than cycling through positions. The team size remains closely held. In September 2023, Lake Bleu closed its fourth healthcare-focused fund, consistent with its pattern of raising dedicated, sector-concentrated pools of capital from institutional investors and family offices seeking pure-play healthcare exposure in Asia. The firm does not operate a separate philanthropic foundation or multi-family office platform. Structurally, Lake Bleu's edge rests on its combination of public-market liquidity with private, late-stage access, uncommon among Hong Kong-based healthcare funds that tend to commit exclusively to one format. Yang's prior experience at Hillhouse — known for its private equity-style public market investing — shaped a mandate that allows the firm to remain invested in publicly listed biotech companies for years, treating them like private holdings rather than beta-driven trades.
General information
Firm type
Generalist
Year founded
2016
AUM
Undisclosed
Location
Region
Asia
Country
Hong Kong
City
Central
Corporate office
Central, Hong Kong
Principals
David Yang
Founder and Chief Investment Officer
Sector focus
Frequently asked questions
Who runs investment decisions at Lake Bleu Capital?
David Yang, the founder and Chief Investment Officer, leads all investment decisions. Before launching Lake Bleu in 2016, Yang worked as a healthcare analyst at Orbimed and Hillhouse Capital, two of the largest healthcare-focused investment firms globally. His role at Hillhouse, a firm known for applying a private-equity mindset to public markets, heavily influenced Lake Bleu's long-duration, concentrated portfolio approach.
Does Lake Bleu invest in public markets or only private companies?
Lake Bleu operates a crossover healthcare strategy, investing in both publicly traded equities and late-stage private companies. The firm's mandate allows it to hold public positions for extended periods, treating them more like private holdings than liquid trading instruments. Confirmed public equity positions have included Wuxi Biologics, while private investments span pre-IPO biotech and pharmaceutical companies in Greater China.
Which sectors does Lake Bleu Capital focus on?
The firm is exclusively dedicated to healthcare. It targets three subsectors: biopharmaceuticals, medical devices, and healthcare services. Lake Bleu looks for companies where scientific complexity or evolving regulatory environments in China and Asia create valuation gaps.
What investment stages does Lake Bleu typically target?
On the private side, Lake Bleu targets late-stage, pre-IPO companies within healthcare. On the public side, it buys into already-listed healthcare companies, often biotechnology firms. It does not typically engage in early-stage seed or Series A venture rounds.
What geographies does Lake Bleu concentrate its investments in?
The firm's primary focus is Greater China, where it has backed companies like Zai Lab and CStone Pharmaceuticals. It also selectively invests in US-based biotechnology companies, particularly those pursuing regulatory approval or commercialization partnerships in Asia.
Is Lake Bleu structured as a family office or a fund manager?
Lake Bleu Capital is an asset manager. It raises dedicated healthcare-focused funds from a mix of institutional investors and family offices. It is not a single family office and does not operate a multi-family office platform.
How does David Yang's background at Hillhouse Capital inform Lake Bleu's strategy?
At Hillhouse, Yang observed a model that applied private equity due-diligence rigor to public market investing, holding positions for years rather than quarters. He imported that philosophy to Lake Bleu, which holds concentrated, conviction-weighted positions in healthcare and avoids short-term trading or broad diversification across sectors.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on registered investment advisers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: